In-center self-care hemodialysisis associated with better outcomes than traditional in-center hemodialysis.
Modalities of renal replacement therapy are categorized into in-center hemodialysis and home therapies. A subset of hemodialysis patients referred to as in-center self-care hemodialysis (ICSCHD) receive patient training as if they were going home but instead perform their dialysis in-center with minimal staff support. Preliminary data suggests ICSCHD is associated with better outcomes than traditional in-center hemodialysis. We looked at ICSCHD patients initiating maintenance dialysis from April 1, 2011 to March 30, 2014 and compared them at a 1:2 ratio to propensity-score matched controls from surrounding facilities within the same catchment area. The median follow-up was 14 months. Patients on ICSCHD had lower mortality rate (0.02 vs 0.07 per patient year; p <0.05), fewer hospitalization events (0.82 vs. 1.70 per patient year; p = 0.008) and fewer missed treatments (1.1% vs 3.8% of all treatments; p = 0.005) than matched controls. We concluded that patients on ICSCHD had lower mortality rates and fewer hospital days than well-matched controls and spent more time on dialysis and missed fewer treatments. Establishing a facility-wide culture of care promoting patient engagement in ICSCHD may have contributed to these findings.
Read More: http://www.nephrologynews.com/outcomes-among-patients-receiving-center-self-care-hemodialysis/
While Omada Health’s Prevent program is designed for individuals with prediabetes, it can be adapted to patients who already have diabetes, because the program is built on behavior change and modification, explained Mike Payne, MBA, MSci, chief healthcare development officer at Omada Health.
Silk Road Medical Announces New Medicare Coverage Option for TransCarotid Artery Revascularization (TCAR) Procedures
Via: PR Newswire
Medicare to Cover Procedures within the TCAR Surveillance Project Sponsored by the Society for Vascular Surgery
NEW CAROTID ARTERY STENT PROCEDURE TO BE EVALUATED BY
Edward R Jones, MD, MBA, FACP LaRhondd James, RN Sophid Rosen, PhD
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer
Results Expected in the First Half of 2017
NN&I interviewed Leslie Trigg, CEO of Outset Medical, on the company's new Tablo dialysis machine, which is aimed at clinics who want to develop the self-care option for patients.
By: Sarah S. Prichard, MD, FRCP(C) Glenn M. Chertow, MD, MPH
Innovator: Leslie Trigg
MedtechVision 2016: Global Medtech